Stock CANTA CANTARGIA AB
Add to a list
To use this feature you must be a member
Log inSign up

Cantargia AB Stock

Equities

CANTA

SE0006371126

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
4.99 SEK +2.13% Intraday chart for Cantargia AB +5.14% +33.49%
Jun. 14 Cantargia AB Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10 CI
Jun. 11 Cantargia Appoints New Chief Business Officer MT

Financials

Sales 2024 * - Sales 2025 * 578M 54.96M Capitalization 917M 87.23M
Net income 2024 * -294M -27.98M Net income 2025 * -98M -9.33M EV / Sales 2024 * -
Net Debt 2024 * 56.6M 5.39M Net Debt 2025 * 657M 62.51M EV / Sales 2025 * 2.72 x
P/E ratio 2024 *
-2.31 x
P/E ratio 2025 *
-2.67 x
Employees 23
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.23%
More Fundamentals * Assessed data

Chart Cantargia AB

Dynamic Chart

Latest news about Cantargia AB

Cantargia AB Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10 CI
Cantargia Appoints New Chief Business Officer MT
Cantargia AB Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024 CI
Cantargia Asco Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting Neuropathy CI
Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy CI
Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024
Cantargia AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition CI
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal CI
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer CI
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis CI
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia CI
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis CI
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer CI
Transcript : Cantargia AB, 2023 Earnings Call, Feb 22, 2024
More news

Latest transcript on Cantargia AB

Logo Cantargia AB
Cantargia AB, Q1 2024 Earnings Call, May 21, 2024
More transcripts

Analyst Recommendations on Cantargia AB

Cantargia AB Reports High Response Rates with CAN04 Combination Therapy in NSCLC and Presents Next Development Steps CI
More recommendations

Press releases Cantargia AB

Cantargia reports further progress in ongoing phase 1 clinical trial with CAN10 AQ
Cantargia strengthen management team with the appointment of Ton Berkien as Chief Business Officer AQ
Cantargia ASCO presentation highlights positive clinical data on nadunolimab counteracting neuropathy AQ
Cantargia presents new positive clinical data on nadunolimab counteracting chemotherapy induced neuropathy AQ
Annual General Meeting in Cantargia AB (publ) AQ
More press releases

Quotes and Performance

1 day+2.13%
1 week+5.14%
Current month+3.96%
1 month+39.23%
3 months+84.81%
6 months+21.95%
Current year+33.49%
More quotes

Highs and lows

1 week
4.24
Extreme 4.24
5.08
1 month
3.28
Extreme 3.276
5.20
Current year
2.56
Extreme 2.564
5.20
1 year
2.56
Extreme 2.564
6.08
3 years
2.56
Extreme 2.564
27.92
5 years
2.56
Extreme 2.564
71.80
10 years
2.56
Extreme 2.564
71.80
More quotes

Managers and Directors - Cantargia AB

Managers TitleAgeSince
Göran Forsberg CEO
 Chief Executive Officer 61 14-07-08
Patrik Renblad DFI
 Director of Finance/CFO 54 23-06-14
David Liberg CTO
 Chief Tech/Sci/R&D Officer 55 14-12-31
Members of the board TitleAgeSince
Magnus Nilsson BRD
 Director/Board Member 68 21-05-25
Gunnar Magnus Modee Persson CHM
 Chairman 64 15-12-31
Damian Marron BRD
 Director/Board Member 62 21-05-25
More insiders

Quotes

Date Price Change Volume
24-06-14 4.99 +2.13% 412,566
24-06-13 4.886 +6.22% 282,698
24-06-12 4.6 +2.18% 434,280
24-06-11 4.502 -2.00% 196,845
24-06-10 4.594 -3.20% 154,756

Delayed Quote Nasdaq Stockholm, June 14, 2024 at 12:00 pm EDT

More quotes

Company Profile

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Sector
Biotechnology & Medical Research
Calendar
2024-08-27 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.99 SEK
Average target price
12.67 SEK
Spread / Average Target
+153.84%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CANTARGIA AB Stock Cantargia AB
+33.49% 87M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.15% 124B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.02% 112B
BIONTECH SE Stock BioNTech SE
-12.75% 22.22B
ARGENX SE Stock argenx SE
+5.07% 22.94B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.94% 16.87B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.86% 17.02B
GENMAB A/S Stock Genmab A/S
-14.97% 16.88B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.80% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.39% 11.61B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CANTA Stock